We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 147 results

  1. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery

    Achieving efficacious systemic levels of orally administered peptides is incredibly challenging due to the significant barriers to their...

    Andrew L. Lewis, Nicholas McEntee, ... Asma Patel in Drug Delivery and Translational Research
    Article 22 May 2021

  2. Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease that can progress to end-stage...

    Inês Domingues, Hafsa Yagoubi, ... Ana Beloqui in Drug Delivery and Translational Research
    Article Open access 13 April 2024

  4. Elucidating the Degradation Pathways of Human Insulin in the Solid State

    While there have been significant advances in the development of peptide oral dosage forms in recent years, highlighted by the clinical and...

    Andrew Fagan, Lorraine M. Bateman, ... Abina M. Crean in Journal of Analysis and Testing
    Article Open access 06 May 2024

  7. Medikamente zur Behandlung von Essstörungen und Adipositas

    Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von...
    Hubertus Himmerich, Otto Benkert in Kompendium der Psychiatrischen Pharmakotherapie
    Chapter 2023

  8. Diabetes

    Diabetes is a defect in sugar metabolism, along with resistance to insulin. Obesity is a significant factor. Diabetes must be carefully controlled in...
    Ronald M. Caplan in Long Life Strategy
    Chapter 2023

  11. Advanced Formulation Approaches for Proteins

    Proteins and peptides are highly desirable as therapeutic agents, being highly potent and specific. However, there are myriad challenges with...
    Corinna S. Schlosser, Gareth R. Williams, Karolina Dziemidowicz in Drug Delivery and Targeting
    Chapter 2023

  15. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

    Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent...

    Fatima Quddos, Zachary Hubshman, ... Warren K. Bickel in Scientific Reports
    Article Open access 28 November 2023

  18. Top product forecasts for 2024

    Paul Verdin in Nature Reviews Drug Discovery
    Article 07 December 2023

  19. GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience

    Introduction

    Glucagon-like peptide-1 receptor agonist use has increased over the last decade for glycemic control in type 2 diabetes mellitus,...

    Stacy Marshall, Erin Ryan, ... Suhkshant Atti in Journal of Medical Toxicology
    Article Open access 11 June 2024
Did you find what you were looking for? Share feedback.